← All indications
Kidney Neoplasms
Tumors or cancers of the KIDNEY.
Subtype terms (3)
More specific conditions that are subtypes of Kidney Neoplasms in the MeSH hierarchy.
- Carcinoma, Renal Cell
632 drugs (190 approved, 442 experimental)
- Nephroma, Mesoblastic
- Wilms Tumor
83 drugs (51 approved, 32 experimental)
Drugs by status
Phase 4 trials (23)
- human dehydrated amnion chorion allograft
- droperidol
- papaverine
- rifapentine
- nivolumab
- sevoflurane
- perflutren protein-type a microspheres
- cabozantinib
- propofol
- vitamin d3
- indocyanine green
- lidocaine
- polyethylene glycol
- dexmedetomidine
- hydroxyethyl starch
- sodium chloride
- aldesleukin
- bupropion
- ipilimumab
- nicotine
- fentanyl
- bupivacaine
- aminophylline
Phase 3 trials (34)
- interferon alpha-2b
- doxorubicin
- alanine
- axitinib
- docetaxel
- mannitol
- dactinomycin
- hypericum perforatum
- isotretinoin
- everolimus
- temsirolimus
- manganese chloride
- cyclophosphamide
- etoposide
- thalidomide
- vincristine
- shark cartilage extract ae-941
- ifosfamide
- sunitinib
- medroxyprogesterone
- atezolizumab
- sorafenib
- sargramostim
- carboplatin
- fluorouracil
- vitespen
- atorvastatin
- pembrolizumab
- bevacizumab
- lenvatinib
- +4 more
Phase 2 trials (189)
- vinorelbine
- mk-1775
- 7-hydroxystaurosporine
- estramustine
- tislelizumab
- allogeneic natural killer cells
- diphenhydramine
- talazoparib
- hydromorphone
- arsenic trioxide
- beclomethasone
- allogeneic tumor cell vaccine
- htl0039732
- n-(4-hydroxyphenyl)all-trans retinamide
- denosumab
- imatinib
- genistein
- Belzutifan
- aur109
- becatecarin
- ivocizumab
- x-82
- bortezomib
- poly-iclc
- defactinib
- dasatinib
- zinc dichloride
- trastuzumab emtansine
- nkt2152
- hb0025
- +159 more
Phase 1 trials (61)
- mogamulizumab
- py314
- nxp900
- 124i-iodo-azomycin galacto-pyranoside
- tak-500
- odm-203
- fluoropaclitaxel
- recombinant oncolytic herpes simplex virus type 1 (r130)
- panitumumab
- [203pb]vmt-α-net
- mdx-1411
- seneca valley virus
- cngrc peptide-tnf alpha conjugate
- ro7198457
- do-2
- orantinib
- gem3psca
- tucotuzumab celmoleukin
- brodalumab
- (pg13-a(f/k-f-sgsg-t2a-b (opt) (2g-1 tcr) retroviral vector-transduced lymphocyte
- cetuximab
- dacarbazine
- stk1-ligand
- mesna
- ags-16m18
- gallium-68-dotatate
- y90 conjugated chimeric g250
- il-4(38-37)-pe38kdel
- herv-e tcr transduced cd8+/cd34+ t cells in hlaa* 11:01 positive patients
- panobinostat
- +31 more
Other trials (31)
- pentetic acid
- zr-dfo-r8b4
- rituximab
- [18f]rccb6
- vegfr2
- proparacetamol
- fructose
- traumeel
- piflufolastat
- zr-dfo-rb6
- ga-nota-r8b4
- 111in-j591
- calcium lactate
- sulfur hexafluoride lipid-type a microspheres
- ga-nota-rd06
- zr-dfo-rd06
- nefopam
- iodine
- octreotide
- CX4945
- varenicline
- resca-r8b4
- autologous mononuclear stem cell
- gabapentin
- ropivacaine
- alemtuzumab
- caspofungin
- glucose
- pyruvate
- resca-rd06
- +1 more
Organizations
Organization Involved with Phase 4 Indications (12)
Organization Involved with Phase 3 Indications (68)
- AstraZeneca
- Pfizer
- AEterna Zentaris
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- Oxford BioMedica
- SFJ Pharmaceuticals, Inc.
- Wilex
- Agenus Inc.
- National Institutes of Health (NIH)
- Central European Cooperative Oncology Group
- Medical Research Council
- Huazhong University of Science and Technology
- University of Pennsylvania
- University of Pittsburgh
- Canadian Cancer Trials Group
- Cancer and Leukemia Group B (CALGB)
- Cancer Research UK
- Centre Leon Berard
- Children's Cancer and Leukaemia Group
- University of London
- Cornell University
- Harvard University
- Eastern Cooperative Oncology Group
- Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany
- HonorHealth Research Institute
- Katholieke Universiteit Leuven
- Lund University
- Loyola University
- New York University
- Oregon Health and Science University
- +38 more
Organization Involved with Phase 2 Indications (151)
- Pierre Fabre
- Aceragen, Inc/
- Sirna Therapeutics
- Eisai
- Celgene
- Amgen
- Onyx
- Merck
- Pharmacyclics
- Eli Lilly
- Exelixis
- Genentech
- MedImmune
- Sanofi
- Novartis
- Bayer
- BeOne Medicines
- Celldex Therapeutics
- Hope Cancer Institute, Inc.
- Lantheus Medical Imaging
- Mirati Therapeutics Inc.
- Oncotech
- Shenzhen BinDeBio Ltd.
- Syndax Pharmaceuticals
- Theradex
- Threshold Pharmaceuticals
- Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.
- Epizyme, Inc.
- Peloton Therapeutics, Inc.
- Steba Biotech S.A.
- +121 more
Organization Involved with Phase 1 Indications (41)
- Active Biotech AB
- Takeda
- Roche
- Astellas
- Schering-Plough
- Merck Serono
- Five Eleven Pharma, Inc.
- GlaxoSmithKline
- Kyowa Hakko Kirin
- NanOlogy, LLC
- Neurocrine Biosciences
- Oncovir, Inc.
- ZymoGenetics
- Agensys, Inc.
- Biontech
- Cytheris
- Shanghai Junshi Bioscience Co.,Ltd.
- British Columbia Cancer Agency
- Institut fur Klinische Forschung, Germany
- Julius-Maximilians University
- Northwestern University
- Osaka University
- Virginia Commonwealth University
- Peking University
- University of California, Irvine
- University of Copenhagen
- US Biotest
- NewLink Genetics Inc
- Doris Duke Charitable Foundation
- Novotech
- +11 more
Organization Involved with Other Experimental Indications (11)